A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

This study is currently recruiting participants.

Verified August 2010 by Stanford University

First Received on January 29, 2010. Last Updated on August 19, 2010 History of Changes

Sponsor:	Stanford University
Collaborators:	National Institutes of Health (NIH) Providence Foundation
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT01060319

Purpose

We hypothesize that all human malignancies harbour a subpopulation of tumor initiating cells/cancer stem cells (CSCs) that drives tumor development and potentially recurrence or metastasis of the disease. The primary aim of this study is to develop strategies for prospective isolation/enrichment of CSCs from human tumors of different tissue origins. In addition, we will characterize the signaling pathways and/or tumor specific antigens that are specific for CSCs, in order to specifically target these CSCs as the endpoint of this study.

Condition
Bladder Cancer Skin Cancers Bladder (Urothelial, Transitional Cell) Cancer Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

Resource links provided by NLM:

Genetics Home Reference related topics: bladder cancer

MedlinePlus related topics: Bladder Cancer Cancer Skin Cancer

U.S. FDA Resources

Further study details as provided by Stanford University:

Biospecimen Retention: Samples With DNA

Bladder cancer specimens

Estimated Enrollment:	40
Study Start Date:	December 2009
Estimated Study Completion Date:	December 2012
Estimated Primary Completion Date:	December 2012 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

non-melanoma skin and bladder cancer patients that are recommended for surgical removal of tumor tissues

Criteria

Inclusion Criteria:N/A. We will recruit all non-melanoma skin and bladder cancer patients that are recommended for surgical removal of tumor tissues. This includes patients from all ages, gender and ethnicity background. Our sample collection criteria based on the tumor size of individual (e.g. tumor samples will only be collected if it will not affect the pathological diagnosis or treatment procedures of patients).

Exclusion Criteria:N/A

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01060319

Contacts

Contact: Linda Quinn

(650) 723-6520

ljquinn@stanford.edu

Locations

United States, California
Stanford University School of Medicine	Recruiting
Stanford, California, United States, 94305
Contact: Linda Quinn 650-723-6520 ljquinn@stanford.edu
Contact: Cancer Clinical Trials Office (650) 498-4073 ljquinn@stanford.edu
Principal Investigator: Irving L. Weissman M.D.
Sub-Investigator: Joseph C. Presti Jr.
Sub-Investigator: Joseph C. Liao
Sub-Investigator: Hayes Gladstone
Sub-Investigator: Robert Chin

Sponsors and Collaborators

Stanford University

National Institutes of Health (NIH)

Providence Foundation

Investigators

Principal Investigator:

Irving L. Weissman M.D.

Stanford University

More Information

No publications provided

Responsible Party:	Irving L. Weissman M.D., Stanford University School of Medicine
ClinicalTrials.gov Identifier:	NCT01060319 History of Changes
Other Study ID Numbers:	SU-11062009-4360, BLDR0011
Study First Received:	January 29, 2010
Last Updated:	August 19, 2010
Health Authority:	United States: Institutional Review Board

Additional relevant MeSH terms:

Urinary Bladder Neoplasms
Skin Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site

Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Skin Diseases

ClinicalTrials.gov processed this record on February 09, 2012